

Cabotegravir

Status – Access to Investigational Cabotegravir for **treatment** of HIV-1 infection in adult and adolescents aged 12 and over weighing at least 35kg, viremic with VL >200 copies/ml, with documented resistance or previous failure of NNRTI-based regimen that **would prohibit the use of rilpivirine long-acting injectable**, who have limited available alternatives and/ or limited treatment options and in a live saving situation.
AVAILABLE in United States ONLY.

Status – Access to Investigational Cabotegravir for HIV **prevention** is **AVAILABLE outside Africa, Australia, Austria, Belgium, Botswana, Brazil, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania Malawi, Malta, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, South Africa, Spain, Sweden, Switzerland, United Kingdom, United States and Zimbabwe.**

Fostemsavir

Status – Access to investigational fostemsavir (600 mg extended-release tablets) for the treatment of HIV-1 infection for use in combination with other antiretroviral therapies in heavily treatment experienced adults is **AVAILABLE outside of Argentina, Australia, Belgium, Brazil, Canada, France, Germany, Greece, Italy, Luxembourg, Spain, United Kingdom and the United States.**

Refer to ClinicalTrials.gov identifier NCT04233047

Dolutegravir Dispersible Tablets

Status – Access to Investigational Dolutegravir Dispersible Tablet formulation is **AVAILABLE Outside of the following countries:**

Angola	Denmark	Kenya	Slovenia
Austria	Dominican Republic	Lesotho	South Sudan
Belgium	Eswatini	Liberia	Spain
Benin	Ethiopia	Malawi	Sweden
Botswana	Finland	Mali	Switzerland
Burundi	France	Mauritius	Tanzania
Cambodia	Gambia	Mozambique	Uganda
Cameroon	Germany	Namibia	United Kingdom
Canada	Greece	Netherlands	United States
Chad	Guyana	Nigeria	Venezuela
Congo	Haiti	Norway	Zambia
Congo (Democratic Republic of)	Hungary	Papua New Guinea	Zimbabwe
Cote D'Ivoire	India	Poland	
Croatia	Ireland	Serbia	
Czech Republic	Israel	Slovakia	

Tivicay PD (dolutegravir) tablets for oral suspension, which are used in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in paediatric patients (treatment-naïve or -experienced but INSTI- naïve) aged at least four weeks and weighing at least 3kg.

Triumeq paediatric Dispersible Tablets

Status – Access to Investigational Triumeq paediatric Dispersable Tablet(s) is **AVAILABLE outside of the United States.**